Basic Information
Essex Bio-Technology Limited ("EssexBio Group" and "Company") was incorporated in the Cayman Islands on July 31, 2000, and listed on the Hong Kong Stock Exchange on June 27, 2001. Essex focuses on the development of biopharmaceutical drugs based on recombinant DNA technology. It is mainly engaged in the production and sales of biopharmaceutical products for the treatment of surface wounds and ocular wounds. The Group is also involved in the research and development of new indications for bFGF products and other ophthalmic pharmaceutical projects. It has successfully developed a series of genetically engineered biologics, three of which are classified as National Class I new drugs. The Company's main brands are Beifuji, Beifushu, and Beifuxin.